Literature DB >> 23846402

Vitamin B12 level may be related to the efficacy of single ketamine infusion in bipolar depression.

A Permoda-Osip1, J Dorszewska, A Bartkowska-Sniatkowska, M Chlopocka-Wozniak, J K Rybakowski.   

Abstract

The single infusion of ketamine, an N-methyl-d-aspartic acid (NMDA) glutamate receptor antagonist, exerts a therapeutic effect in both unipolar and bipolar depression. Homocysteine (HCY) acts agonistically on the NMDA receptor, hyperhomocysteinemia is related to depression, and folic acid and vitamin B12 are associated with HCY system. We estimated the serum levels of these substances in 20 bipolar depressed patients before ketamine infusion. 10 patients responded favorably to this procedure, as their score on the Hamilton depression rating scale, compared to baseline, was reduced by more than 50%, after 7 days. The vitamin B12 level was significantly higher in "responders" compared to the remaining patients. No differences between the 2 groups were found with regard to HCY, folic acid levels and such clinical factors as age, duration of illness and duration of current episode. These preliminary data suggest that the vitamin B12 level may be connected with the efficacy of ketamine infusion in bipolar depression. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23846402     DOI: 10.1055/s-0033-1349861

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  10 in total

1.  Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine.

Authors:  N B Lundin; M J Niciu; D A Luckenbaugh; D F Ionescu; E M Richards; J L Vande Voort; N E Brutsche; R Machado-Vieira; C A Zarate
Journal:  Pharmacopsychiatry       Date:  2014-06-23       Impact factor: 5.788

Review 2.  Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.

Authors:  Chadi G Abdallah; Gerard Sanacora; Ronald S Duman; John H Krystal
Journal:  Annu Rev Med       Date:  2014-10-17       Impact factor: 13.739

3.  Clinical predictors of ketamine response in treatment-resistant major depression.

Authors:  Mark J Niciu; David A Luckenbaugh; Dawn F Ionescu; Sara Guevara; Rodrigo Machado-Vieira; Erica M Richards; Nancy E Brutsche; Neal M Nolan; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2014-05       Impact factor: 4.384

Review 4.  Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.

Authors:  Mark J Niciu; Dawn F Ionescu; Erica M Richards; Carlos A Zarate
Journal:  J Neural Transm (Vienna)       Date:  2013-12-08       Impact factor: 3.575

Review 5.  Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.

Authors:  Nicolas D Iadarola; Mark J Niciu; Erica M Richards; Jennifer L Vande Voort; Elizabeth D Ballard; Nancy B Lundin; Allison C Nugent; Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Ther Adv Chronic Dis       Date:  2015-05       Impact factor: 5.091

6.  Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis.

Authors:  Gustavo C Medeiros; Todd D Gould; William L Prueitt; Julie Nanavati; Michael F Grunebaum; Nuri B Farber; Balwinder Singh; Sudhakar Selvaraj; Rodrigo Machado-Vieira; Eric D Achtyes; Sagar V Parikh; Mark A Frye; Carlos A Zarate; Fernando S Goes
Journal:  Mol Psychiatry       Date:  2022-06-27       Impact factor: 15.992

Review 7.  Homocysteine levels in schizophrenia and affective disorders-focus on cognition.

Authors:  Ahmed A Moustafa; Doaa H Hewedi; Abeer M Eissa; Dorota Frydecka; Błażej Misiak
Journal:  Front Behav Neurosci       Date:  2014-10-06       Impact factor: 3.558

Review 8.  Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.

Authors:  Carola Rong; Caroline Park; Joshua D Rosenblat; Mehala Subramaniapillai; Hannah Zuckerman; Dominika Fus; Yena L Lee; Zihang Pan; Elisa Brietzke; Rodrigo B Mansur; Danielle S Cha; Leanna M W Lui; Roger S McIntyre
Journal:  Int J Environ Res Public Health       Date:  2018-04-17       Impact factor: 3.390

9.  Nitrous oxide as a putative novel dual-mechanism treatment for bipolar depression: Proof-of-concept study design and methodology.

Authors:  Mikaela K Dimick; Danielle Omrin; Bradley J MacIntosh; Rachel H B Mitchell; Daniel Riegert; Anthony Levitt; Ayal Schaffer; Susan Belo; John Iazzetta; Garfield Detzler; Mabel Choi; Stephen Choi; Beverley A Orser; Benjamin I Goldstein
Journal:  Contemp Clin Trials Commun       Date:  2020-06-23

10.  The Effects of Plasma Homocysteine Level on the Risk of Three Major Psychiatric Disorders: A Mendelian Randomization Study.

Authors:  Jing Yu; Ranran Xue; Qiuling Wang; Hao Yu; Xia Liu
Journal:  Front Psychiatry       Date:  2022-03-21       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.